Amgen drug tied to death risks in tests as transfusion substitute

A new study of Amgen's Aranesp said it was linked to an almost 45% increase in death in trials testing it for reducing the need for blood transfusions in anemic cancer patients. Aranesp already is approved for treating the anemia itself, a side effect of chemotherapy, and an FDA advisory panel plans to meet in May to consider the entire class of erythropoiesis-stimulating agents.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA